Search

Now showing items 1-2 of 2

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, Sridharan; Herndon, James Emmett II; Marcello, JE; ... (13 authors) (Br J Cancer, 2009-12-15)

BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade ...

Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.

Bigner, DD; Kuan, Chien-Tsun; Kumar, U; McLendon, Roger E; Wikstrand, CJ; Zalutsky, Michael Rod (Hybridoma (Larchmt), 2009-12)

Somatostatin receptor 2 (SSTR2) is expressed by most medulloblastomas (MEDs). We isolated monoclonal antibodies (MAbs) to the 12-mer (33)QTEPYYDLTSNA(44), which resides in the extracellular domain of the SSTR2 amino terminus, ...